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Background
Activation of the  opioid (KOP) receptor results in anti-
nociceptive actions, while it is not involved in the
unwanted effects including respiratory depression, depen-
dence or abuse liability, as in the case of the µ opioid
(MOP) receptor. Therefore, KOP agonists appear to pos-
sess some advantages over the most widely used MOR
analgesics. Besides the analgesic activity, KOP agonists
have also shown other beneficial effects such as anti-pruri-
tic, anti-arthritic, anti-inflammatory, and neuroprotective
effects. At present, the main classes of available chemically
distinct KOP agonists include benzomorphans, morphi-
nans, arylacetamides, diterpenes and peptides. Herein, we
present a new molecular scaffold for KOP ligands of the
class of diphenethylamines and biological investigations on
in vitro and in vivo opioid activities.
Methods
Synthesis of the novel KOP ligands was accomplished by
multi-step syntheses. Chinese hamster ovary (CHO) cell
membranes expressing human opioid receptors were used
in radioligand binding and [35S]GTPgS functional assays.
Antinociceptive activities were assessed in mice using the
writhing test.
Results
Several novel ligands were synthesized and pharmacologi-
cally evaluated. Among them, HS665 proved to be the
derivative with the highest selectivity for the KOP receptor
vs. the other two types, MOP and δ opioid (DOP) recep-
tors (selectivity ratios KOP/MOP >1,000 and KOP/DOP
>20,000), and KOP agonist potency. In vivo, this derivative
produced dose-dependent and significant antinociceptive
actions in a mouse model of visceral pain (acetic acid-
induced writhing) after subcutaneous administration,
being equipotent to the standard KOP agonist U50,488.
Antinociceptive effects of HS665 were reversed by the
KOP-selective antagonist nor-binaltorphimine demon-
strating a KOP receptor-mediated mechanism of the anti-
nociceptive action. HS665 has also recently been prepared
in tritium-labeled form ([3H]HS665), which can be used as
research tool to characterize KOP actions at the cellular
and molecular level and to establish the in vitro opioid
activity profile of new ligands.
Conclusions
This study shows that through appropriate molecular
manipulations, a new class of ligands interacting with
KOP has been identified, namely HS665 and derivatives
thereof. Such novel KOP ligands, besides the scientific
value as pharmacological tools, may also have the potential
of emerging as novel therapeutics for human disease
states.
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